Cancer Vaccines: From Research to Clinical Practice
Editat de Adrian Bot, Mihail Obrocea, Francesco M. Marincolaen Limba Engleză Hardback – 23 aug 2011
Cancer Vaccines: From Research to Clinical Practice:
- Analyzes the most promising classes of investigational immunotherapies, integrating their scientific rationale and clinical potential
- Discusses "theranostics" as pertaining to immunotherapy, i.e., using molecular diagnostics to identify patients that would most likely benefit from a therapy
- Presents the new paradigm of biomarker guided R&D and clinical development in immunotherapy of cancer
- Reviews bottlenecks in translational process of immunotherapies and offers strategies to resolve them
Preț: 1072.72 lei
Preț vechi: 1446.92 lei
-26% Nou
Puncte Express: 1609
Preț estimativ în valută:
205.30€ • 216.59$ • 171.09£
205.30€ • 216.59$ • 171.09£
Carte tipărită la comandă
Livrare economică 02-16 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781841848297
ISBN-10: 1841848298
Pagini: 296
Ilustrații: 11 b/w images, 63 color images, 14 tables, 5 color halftones, 11 line drawings, 58 color line drawings and 6 equations
Dimensiuni: 178 x 254 x 23 mm
Greutate: 0.93 kg
Ediția:Revised.
Editura: CRC Press
Colecția CRC Press
ISBN-10: 1841848298
Pagini: 296
Ilustrații: 11 b/w images, 63 color images, 14 tables, 5 color halftones, 11 line drawings, 58 color line drawings and 6 equations
Dimensiuni: 178 x 254 x 23 mm
Greutate: 0.93 kg
Ediția:Revised.
Editura: CRC Press
Colecția CRC Press
V-ar putea interesa
-
Cancer Causes and Controversies: Understanding Risk Reduction and PreventionBernard Kwabi-Addo-8%Preț: 307.62 lei336.15 lei -
-17%Preț: 315.27 lei380.18 lei -
-5%Preț: 1067.56 lei1123.74 lei -
Genetic ImmunizationAdrian Bot-5%Preț: 975.65 lei1026.99 lei -
Immunologic Signatures of RejectionFrancesco M. Marincola-5%Preț: 1056.30 lei1111.90 lei -
Concise History of Breast CancerMarc Lacroix-27%Preț: 517.27 lei710.44 lei -
Brain Cancer, Tumor Targeting & Cervical CancerElena K. Salvatti-27%Preț: 650.27 lei888.68 lei -
-27%Preț: 295.64 lei406.32 lei -
Encyclopedia of Cancer TreatmentTimothy B. Dunn-27%Preț: 2058.59 lei2828.74 lei -
Cancer in the ElderlyIvan Todorov-27%Preț: 782.57 lei1079.15 lei -
Hepatocellular CarcinomaIsabelle Chemin-27%Preț: 1077.01 lei1482.58 lei -
Cancer Stem Cells in Lung CancerKoji Okudela-27%Preț: 295.20 lei406.06 lei -
Genetic & Epigenetic Alterations That Drive Leukemic Stem Cell Self-RenewalJan Jacob Schuringa-27%Preț: 343.70 lei473.63 lei -
Field CancerizationGabriel D. Dukubo-27%Preț: 1931.94 lei2658.57 lei -
Cancer BiomarkersHelen C. Kristoff-27%Preț: 1197.64 lei1649.05 lei -
Targeted Therapy for Solid Tumors & Hematologic MalignanciesAlfonso Quintas-Cardama-27%Preț: 1612.24 lei2222.86 lei -
Molecular Diagnostics for Melanoma: Methods and ProtocolsMagdalena Thurin-5%Preț: 1397.55 lei1471.10 lei -
Lipid Nanocarriers in Cancer Diagnosis and TherapyEliana Souto-5%Preț: 902.27 lei949.76 lei
Public țintă
Professional and Professional ReferenceCuprins
SECTION I - Basic Aspects: Tumor Antigens and Preclinical Modelling. 1. Factoring in antigen processing in designing anti-tumor T-cell vaccines. 2. Outlining the gap between preclinical models and clinical situation. SECTION II - Cell Based, Anti-infectious and Personalized Vaccines. 3. THERAPEUTIC AND PROPHYLACTIC CANCER VACCINES - EMERGING PERSPECTIVES FROM ALLOGENEIC AND INFECTIOUS DISEASE VACCINES. 4. Personalized Cancer Vaccines. 5. Dendritic cell vaccines for gliomas. SECTION III. INTRACEREBRAL HEMORRHAGE (ICH). 6. Peptide based active immunotherapy in cancer. 7. Multimodality Immunization Approaches to Improve on DNA Vaccines for Cancer. 8. Bidirectional Bedside Lab Bench Processes and Flexible Trial Design as a Means to Expedite the Development of Novel Immunotherapeutics. 9. Diagnostic approaches for selecting patient-customized therapies, obviating tumor variability to maximize therapeutic effect.
Notă biografică
ADRIAN BOT is Senior Director of Scientific Management and Acting Head of Translational Medicine at MannKind Corporation, in Valencia, California. He obtained his M.D. at the University of Medicine and Pharmacy in Timisoara, Romania and his Ph.D. in Biomedical Sciences at Mount Sinai School of Medicine in New York. He previously held appointments at the Scripps Research Institute and Alliance Pharmaceutical Corporation in San Diego. Dr. Bot authored more than one hundred publications and patents in oncology, vaccines, drug delivery technologies and immunotherapy. He is the Editor-in-Chief of the International Reviews of Immunology and has been on advisory boards of several organizations.
MIHAIL OBROCEA is Vice President, Clinical Development, MannKind Corporation, Paramus, New Jersey. Dr. Obrocea received his M.D. from the Faculty of Medicine and Pharmacy, Bucharest, Romania. He is a medical oncologist with over 10 years of academic and industry experience in oncology clinical trials, including biologic agents, small molecules and cytotoxic agents. Dr. Obrocea has published in oncology peer-reviewed literature, and has various patents in the field of biotechnology.
MIHAIL OBROCEA is Vice President, Clinical Development, MannKind Corporation, Paramus, New Jersey. Dr. Obrocea received his M.D. from the Faculty of Medicine and Pharmacy, Bucharest, Romania. He is a medical oncologist with over 10 years of academic and industry experience in oncology clinical trials, including biologic agents, small molecules and cytotoxic agents. Dr. Obrocea has published in oncology peer-reviewed literature, and has various patents in the field of biotechnology.
Descriere
Recent advances in immunology and biology have opened new horizons in cancer therapy—including immunotherapies and cancer vaccines—for both solid and blood borne cancers. This book is the first text in the field to bring immunotherapy treatments from the laboratory trial to the bedside for the practicing oncologist. It discusses "theranostics" as pertaining to immunotherapy, presents the new paradigm of biomarker guided R&D, and discusses clinical development. The book also reviews bottlenecks in translational process of immunotherapies and offers strategies to resolve them.